Intravenous (IV) Equipment Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Global Intravenous (IV) Equipment Market Trends and Insights

Rising Prevalence of Chronic Diseases Requiring Long-Term IV Therapy

Diabetes affects 537 million adults and often necessitates intravenous intervention for complications, underpinning predictable demand across the IV therapy devices market^{[2]Source: MIT News, “Closed-Loop Drug-Delivery System Could Improve Chemotherapy,” news.mit.edu} . Aging populations in North America, Europe, and Japan further widen the chronic-care pool that relies on multi-drug regimens unsuitable for oral delivery. MIT’s CLAUDIA system exemplifies the push toward closed-loop chemotherapy that automatically adjusts dosing every five minutes, illustrating how disease complexity spurs advanced infusion adoption. Payers support home-based IV services to curb readmissions, reinforcing a durable revenue stream for manufacturers that supply patient-centric delivery platforms. Together, these forces propel sustained growth momentum within the IV therapy devices market.

Growth in Home- and Ambulatory-Based Infusion Therapy

Veterans Affairs saved USD 10.2 million by substituting inpatient care with home infusion, validating an economic case that pressures providers to shift toward ambulatory models academic.oup.com. Portable pumps such as the Infonde unit record 95% patient-satisfaction rates, underscoring how mobility-friendly technology supports quality-of-life goals. Pending US legislation proposes stronger Medicare reimbursement, likely boosting patient volumes. During the COVID-19 pandemic, nurses operated pumps outside ICU rooms to reduce exposure risks, accelerating digital-monitoring upgrades. Oncology remains the prime home-care growth engine as patients favor familiar settings for lengthy chemotherapies, reinforcing upward momentum in the IV therapy devices market.

Increasing Surgical Procedures & Hospitalization Rates

Rising surgical volumes across Asia-Pacific require precise perioperative fluid management that smart pumps provide. BD’s HemoSphere Alta platform integrates Hypotension Prediction Index analytics, illustrating how AI-based decision support elevates pump utility during complex procedures. ERAS protocols demonstrated 50% fluid-use reductions without compromising outcomes, driving hospitals to adopt pumps capable of more granular delivery. Minimally invasive techniques and an aging population spur ongoing operating-room demand, sustaining the IV therapy devices market trajectory.

Technological Advancements in Smart Infusion & Needle-Free Systems

FDA guidance now permits software updates under predetermined change-control plans, accelerating AI innovation cycles in infusion devices. Needle-free connectors like Delta P.Valve achieve neonatal-safe flow rates while offering clear visualization to avert infection deltamed.pro. BD’s Nexiva closed catheter reduces blood-exposure risk by 98% and delivers median dwell times of 144.5 hours, boosting clinical productivity. Digital droplet infusion scales down volumes to 57 nL, demonstrating precision leaps that encourage adoption in high-value therapies. Coupled with IoT dashboards, these advancements anchor premium pricing power within the IV therapy devices market.

Product Recalls & Medication-Error Regulatory Scrutiny

The FDA initiated Class I recalls affecting more than 150,000 infusion devices in 2024, including ICU Medical’s Medfusion line, intensifying oversight across the IV therapy devices market. New Quality Management System Regulation, effective February 2026, aligns US rules with ISO 13485:2016 and expands post-market surveillance. Fresenius Kabi’s USD 240 million Ivenix buy-out swiftly encountered warning letters, illustrating compliance risk. Section 524B cybersecurity mandates now form part of pre-market submissions, raising barriers for smaller entrants. While these actions uplift safety, short-run cost spikes can dampen equipment turnover, tempering growth within the IV therapy devices market.

Shift Toward Subcutaneous/Oral Biologics Reducing IV Demand

Large-volume subcutaneous formulations constitute 15% of late-stage pipelines, signaling a channel shift away from intravenous delivery. Merck’s subcutaneous pembrolizumab aims to cut chair-time from hours to minutes, pending September 2025 FDA action drugs.com. Oncology biologics such as daratumumab already demonstrate patient-preference swings toward rapid injections, challenging pump utilization rates. Pharma companies are also exploring eco-friendly delivery devices that sidestep single-use IV disposables. Consequently, manufacturers must showcase superior clinical or economic value to defend share within the IV therapy devices market.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Product Type: Smart Pumps Lead Innovation Wave

IV catheters controlled 37.78% of 2025 revenue as the foundational access tool across settings, securing the single-largest slice of the IV therapy devices market bbraunusa.com. Smart infusion pumps, however, represent the fastest growth at 6.67% CAGR thanks to AI dose-error reduction and cloud analytics. Baxter’s Spectrum IQ earned its seventh Best-in-KLAS award with 97% drug-library compliance, illustrating the performance bar now expected in the IV therapy devices market. Consumables such as tubing and administration sets benefit from steady replacement cycles, ensuring recurring revenue. Needle-free connectors, securement devices, and advanced filters collectively add infection-prevention value, making them attractive add-on sales. Mature drip-chamber components grow modestly yet remain essential, preserving backbone demand throughout the IV therapy devices market.

By End User: Home Care Disrupts Traditional Models

Hospitals retained 48.62% share in 2025, reflecting embedded procurement pathways and the scale of acute-care demand. Home-care settings, advancing at a 6.97% CAGR, illustrate how payer cost controls and patient comfort reorder priorities within the IV therapy devices market. Japanese home-care data show 21.6% of patients need intravenous therapy, yet 75% experience venous-access complications, spotlighting the safety gap that premium devices aim to close. Ambulatory surgery centers absorb spill-over cases as same-day procedures proliferate, requiring compact yet sophisticated pumps. Diagnostic and specialty clinics exploit niche oncology and immunology therapies where controlled infusion remains critical. Value-based care incentives further fuel migration outside hospitals, strengthening multi-setting demand across the IV therapy devices market.

By Application: Oncology Drives Premium Growth

Medication administration comprised 43.92% revenue in 2025, spanning antibiotics to biologics. Yet chemotherapy and oncology applications post the steepest climb at 7.72% CAGR, propelled by rising cancer incidence and regimen complexity. Closed-loop delivery prototypes like CLAUDIA monitor plasma drug levels every five minutes, foreshadowing a new standard of precision in the IV therapy devices market. Fluid and nutrition therapy retains baseline demand in critical-care units, while blood-product infusion requires strict alarm and monitoring features. AI-optimized parenteral nutrition formulations illustrate how application-specific software differentiation can unlock fresh value pools.

Geography Analysis

North America generated 41.85% of global revenue in 2025 owing to robust reimbursement and early technology adoption, reinforcing its anchor position in the IV therapy devices market. Yet Hurricane Helene exposed supply-chain risk, triggering federal initiatives to validate point-of-care fluid manufacturing and argue for broader supplier portfolios. Canada’s universal system and Mexico’s private-hospital build-out add incremental volumes, while a harmonizing regulatory backdrop facilitates cross-border trade.

Asia-Pacific is the fastest-growing region at an 7.96% CAGR, propelled by China’s healthcare-spend trajectory toward RMB 205 trillion by 2030 and incentive schemes that fast-track innovative devices . Japan’s super-aging society intensifies home-infusion uptake despite elevated complication rates, creating openings for safer vascular-access designs. India’s hospital expansion and chronic-disease surge position it as a high-potential adopter once reimbursement barriers ease. South Korea and Australia, with advanced payer systems, foster premium-device adoption that often cascades into neighboring markets, reinforcing Asia-Pacific’s strategic weight within the IV therapy devices market.

Europe delivers steady gains through stringent quality standards and sustainability mandates that spur eco-design innovation. Economic pressure in Southern markets dampens capital purchases, but Northern nations maintain high replacement cycles. Latin America and the Middle East & Africa contribute emerging-market upside: Brazil drives regional scale through public-hospital acquisitions, while GCC states channel oil revenues into specialty-care facilities requiring sophisticated IV infrastructure. South Africa acts as a distribution hub for sub-Saharan adoption. Collectively, these markets diversify revenue streams and cushion regional shocks for participants in the IV therapy devices market.

Regulatory Landscape

Intravenous (IV) equipment is primarily regulated as medical devices, with many IV administration and infusion-related products falling under US FDA Class II pathways with special controls (for example, under 21 CFR Part 880). In August 2024, the FDA issued a final order classifying an intravenous catheter force-activated separation device into Class II (special controls), reinforcing device-specific control expectations for vascular-access risk mitigation.

Quality and post-market obligations tightened in the base-year-to-current-year window. The FDA Quality Management System Regulation (QMSR) became effective on February 2, 2026, updating 21 CFR Part 820 and aligning the US quality system framework more closely with ISO 13485:2016. In the EU, the MDR (Regulation (EU) 2017/745) continues to define conformity assessment and surveillance requirements, and in April 2026 the Medical Device Coordination Group updated classification guidance (MDCG 2021-24 Rev.1), prompting manufacturers to revisit classification rationales for borderline and software-enabled IV technologies. Adoption of ISO 8536-series standards also provides a practical compliance anchor for infusion set performance, including ISO 8536-13:2024 and ISO 8536-16:2025 for gravity feed infusion sets used with volumetric infusion controllers.

Value Chain Analysis

The IV equipment value chain stretches from upstream medical-grade inputs (PVC, polypropylene, polyethylene, stainless steel needle components, and specialized elastomers) through regulated conversion and finishing. Core manufacturing steps include injection molding (connectors, clamps, drip chambers), tube extrusion (catheters and tubing), assembly in controlled environments (commonly ISO Class 8), and terminal sterilization (EtO or gamma), followed by packaging, lot release testing, and quality documentation aligned with ISO 13485 and risk management expectations. For smart infusion pumps, embedded software validation, cybersecurity documentation, and interoperability testing add additional verification burdens before distribution.

Downstream, products move through a mix of direct hospital sales, group purchasing organizations, and distributors, while recurring consumables (administration sets, tubing, connectors, securement) are frequently bundled to support pump ecosystems and standardize protocols. Supply concentration has been a key stress point: Hurricane Helene (September 2024) disrupted Baxter International operations in North Carolina and removed a major share of US IV fluid capacity, which increased the importance of dual sourcing, validated alternate manufacturing, and inventory buffers at providers. Policy and regulator actions during the shortage, including FDA shortage-list management, import facilitation, and outreach via the Office of Supply Chain Resilience, reinforced a supply-continuity lens in procurement and supplier qualification that goes beyond price-focused contracting.

Market Opportunities and Future Outlook

Safety-driven modernization creates whitespace across IV pumps and associated disposables, particularly in software, usability, and connectivity layers. The FDA’s QMSR effective February 2, 2026 raises the operational bar for design controls and post-market surveillance by aligning more tightly with ISO 13485:2016, which increases demand for suppliers that can provide validated updates, traceable software lifecycles, and robust complaint and CAPA systems. This environment favors smart infusion platforms that integrate dose error reduction software with EHR workflows to reduce manual programming steps and support standardized drug libraries in hospitals and home-infusion networks.

Supply resiliency and materials transition are also becoming tangible investment themes. After the Hurricane Helene disruption highlighted dependence on concentrated IV supply, manufacturers and health systems are prioritizing redundancy and domestic capacity where feasible. In July 2026, the Otsuka ICU Medical joint venture announced a USD 500 million investment to expand its Austin, Texas manufacturing footprint, including a new 500,000-square-foot facility aimed at improving supply resiliency and supporting non-DEHP-related requirements. At the same time, recurring Class I recall activity tied to software and alarm integrity, including 2026 correction and recall actions involving large-volume pumps, supports demand for vendors that can demonstrate dependable alarm behavior, drop-event robustness, and rapid field update capability across installed bases.